Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 22.5% in November
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 22.5% in November
Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 19,600 shares, an increase of 22.5% from the November 15th total of 16,000 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily volume of 16,900 shares, the short-interest ratio is presently 1.2 days.
Tempest治疗公司(纳斯达克代码：TPST-GET评级)是11月份空头股数大幅增长的接受者。截至11月30日，空头股数共有1.96万股，比11月15日的1.6万股增加了22.5%。大约0.4%的股票被卖空。以日均成交量16,900股计算，目前短息比率为1.2天。
Analyst Ratings Changes
分析师评级发生变化
A number of research analysts have recently weighed in on TPST shares. William Blair restated an "outperform" rating on shares of Tempest Therapeutics in a research report on Tuesday, November 8th. LADENBURG THALM/SH SH started coverage on Tempest Therapeutics in a research report on Thursday, September 15th. They set a "buy" rating and a $8.00 price objective for the company.
许多研究分析师最近都在买入TPST的股票。威廉·布莱尔在11月8日星期二的一份研究报告中重申了对Tempest治疗公司股票的“跑赢大盘”评级。拉登堡THALM/SH在9月15日星期四的一份研究报告中开始报道Tempest Treeutics。他们为该公司设定了“买入”评级和8.00美元的目标价。
Institutional Inflows and Outflows
机构资金流入和流出
An institutional investor recently bought a new position in Tempest Therapeutics stock. Millennium Management LLC bought a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,675 shares of the company's stock, valued at approximately $29,000. Millennium Management LLC owned 0.13% of Tempest Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 50.26% of the company's stock.
一家机构投资者最近购买了Tempest治疗公司股票的新头寸。根据千年管理有限责任公司在第二季度购买了坦佩斯特治疗公司(纳斯达克：TPST-GET评级)的新股份，根据该公司在最近提交给美国证券交易委员会(美国证券交易委员会)的13F文件中。该基金购买了13,675股该公司股票，价值约29,000美元。在最近的报告期结束时，Millennium Management LLC拥有Tempest Treeutics公司0.13%的股份。对冲基金和其他机构投资者持有该公司50.26%的股票。
Tempest Therapeutics Stock Up 2.7 %
Tempest Treateutics股票上涨2.7%
Tempest Therapeutics Company Profile
Tempest治疗公司简介
(Get Rating)
(获取评级)
Tempest Therapeutics Inc, a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors.
Tempest治疗公司是一家临床阶段的肿瘤学公司，致力于开发治疗癌症的小分子疗法。该公司的两个临床计划是TPST-1495，这是前列腺素E2受体EP2和EP4的双重拮抗剂，目前正处于实体肿瘤的第一阶段试验；以及TPST-1120，是过氧化物酶体增殖物激活受体α的选择性拮抗剂，正处于实体肿瘤的第一阶段试验。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Tempest Therapeutics (TPST)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 免费获取StockNews.com关于Tempest治疗(TPST)的研究报告
- 现在不是购买Lennar的时候，但时机即将到来
- 马伦汽车公司改变游戏规则的消息
- 通货膨胀和能源危机是两列相撞的货运列车--以下是如何做好准备的
- 企业产品合作伙伴是否得到公平评价？
- WhatsApp合作伙伴关系是否会提振MercadoLibre的收益？
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Tempest治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Tempest Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。